Wayne State University

wayne.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

226

Active

39

Phase 3

6

Total enrollment

26,765

Pipeline matrix

Showing 15 of 15 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Low-Dose Cannabidiol—————1
Moderate-Dose Cannabidiol—————1
Yohimbine + Hydrocortisone—————3
Morphine—————1
Alprazolam—————1
Cannabidiol—————1
Etanercept—————1
Tetrahydrocannabinol————2
Ondansetron 8mg—————1
Cannabidiol (CBD) only—————1
Delta-9-tetrahydrocannabinol (THC) only—————1
THC:CBD 1:1—————1
Emicizumab—————1
FVIII—————1
1-(2-[+F]fluoroethyl)-L-tryptophan—————1

Next readouts

  • 2025-08-01
  • 2026-09
  • 2026-12
  • 2027-08-31
  • 2028-12
  • 2029-01
  • 2030-08-31
  • 2030-12-31
  • 2031-09

Top conditions

  • Hypertension10
  • Heroin Dependence7
  • Post Traumatic Stress Disorder6
  • Opioid-Related Disorders6
  • Multiple Sclerosis6
  • Marijuana Abuse6
  • Type 1 Diabetes5
  • Cocaine Abuse or Dependence4

Frequently asked questions about Wayne State University

How many clinical trials does Wayne State University have on ClinicalTrials.gov?
Wayne State University is listed as the lead sponsor on 226 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
How many of Wayne State University's trials are in Phase 3?
6 of Wayne State University's trials are in Phase 3, spread across 15 active drug programs.
What therapeutic areas does Wayne State University focus on?
Wayne State University's most-studied conditions on ClinicalTrials.gov are Hypertension, Heroin Dependence, Post Traumatic Stress Disorder, Opioid-Related Disorders, Multiple Sclerosis.
When are Wayne State University's next clinical trial readouts?
Wayne State University has 9 upcoming primary-completion readouts tracked here; the soonest is “Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section”, expected around 2025-08-01.